Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 21, 2017The Medicine ForumOpen Access

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

View Full Paper
Ask AI
Bookmark
Share

Authors

IPIgor PuzanovADAdi DiabKAK. Abdallah

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Puzanov et al. (2017) studied this question.

synapsesocial.com/papers/6a7d71eb2f2f9d79738b364ehttps://doi.org/10.1186/s40425-017-0300-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non–Small Cell Lung Cancer2017 · 141 citations
  2. 2Toxicities of Immunotherapy for the Practitioner2015 · 657 citations
  3. 3Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents2016 · 236 citations
  4. 4Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease2016 · 344 citations